Chugai Pharmaceutical Co., Ltd.

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Chugai, a member of Roche group, is a Japanese company focused on creating innovative medicinal products which address unmet medical needs. We have been leading therapeutic antibody and oncology market in Japan and have a top-level presence in Japanese pharmaceutical industry.
Chugai has been active in biopharmaceutical research since the 1970’s. Our proprietary products, such as anti-IL-6 monoclonal antibody Actemra®/RoActemra® (tocilizumab), ALK inhibitor Alecensa® (alectinib) and anti-FlXa/FX bispecific antibody Hemlibra® (emicizumab), those of which are now approved worldwide, illustrate our robust drug research and development capabilities.
Chugai is also keen to collaborate with companies who has strong capability in drug discovery and cutting age technology.
Ticker:
Tokyo
Exchange:
4519
Company Type:
Not Provided
Company HQ State:
Not Provided
Company HQ Country:
Japan
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
Tecentriq
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Senior Vice President, Head of Business Development
Chugai Pharmaceutical Co., Ltd.